Right bundle branch block and ventricular septal fibrosis in patients with hypertrophic cardiomyopathy

Kuniyasu Harimoto1, Tatsuya Kawasaki1, Sakiko Honda1

  • 1Department of Cardiology, Matsushita Memorial Hospital, Osaka, Japan.

Insights

Right bundle branch block (RBBB) can indicate ventricular septal fibrosis in hypertrophic cardiomyopathy (HCM) patients without ablation history. This finding aids in non-invasively identifying fibrosis in HCM patients.

Area of Science:

  • Cardiology
  • Biomedical Imaging
  • Electrophysiology

Background:

  • Right bundle branch block (RBBB) is linked to ventricular septal fibrosis in hypertrophic cardiomyopathy (HCM) patients post-alcohol septal ablation.
  • Limited data exists on RBBB and septal fibrosis in HCM patients without prior septal ablation.

Purpose of the Study:

  • To investigate the association between RBBB and ventricular septal fibrosis in HCM patients without a history of alcohol septal ablation.
  • To determine if RBBB can serve as a non-invasive marker for septal fibrosis in this population.

Main Methods:

  • Magnetic resonance late gadolinium enhancement (LGE) was utilized in 59 HCM patients.
  • LGE location and extent were analyzed concerning electrocardiographic features, specifically RBBB.
  • Correlation between LGE volume and QRS duration in RBBB was assessed.

Main Results:

  • HCM patients with RBBB exhibited significantly higher LGE volume compared to those without RBBB (7.3±7.4g/cm vs. 2.9±7.4g/cm, p=0.016).
  • A strong positive correlation was observed between LGE volume and RBBB QRS duration (correlation coefficient=0.93, p=0.023).
  • RBBB demonstrated high specificity (94%) but low sensitivity (21%) for detecting ventricular septal LGE.

Conclusions:

  • RBBB may serve as a simple, non-invasive marker for identifying ventricular septal fibrosis in HCM patients who have not undergone septal ablation.
  • Further research is warranted to validate these findings and their clinical implications.
Abstract

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
801
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
746
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
786
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
595
Dysrhythmias IV: Characteristics of Bradyarrhythmias01:18

Dysrhythmias IV: Characteristics of Bradyarrhythmias

Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...
785
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
936